Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 431

1.

Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.

Unni AM, Harbourne B, Oh MH, Wild S, Ferrarone JR, Lockwood WW, Varmus H.

Elife. 2018 Nov 26;7. pii: e33718. doi: 10.7554/eLife.33718. [Epub ahead of print]

2.

Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1.

Fei DL, Zhen T, Durham B, Ferrarone J, Zhang T, Garrett L, Yoshimi A, Abdel-Wahab O, Bradley RK, Liu P, Varmus H.

Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):E10437-E10446. doi: 10.1073/pnas.1812669115. Epub 2018 Oct 15.

3.

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6030-E6038. doi: 10.1073/pnas.1717782115. Epub 2018 Jun 6.

4.

Improving support for young biomedical scientists.

Alberts B, Hyman T, Pickett CL, Tilghman S, Varmus H.

Science. 2018 May 18;360(6390):716-718. doi: 10.1126/science.aar8405. No abstract available.

PMID:
29773737
5.

Insurance for broad genomic tests in oncology.

Eisenberg R, Varmus H.

Science. 2017 Dec 1;358(6367):1133-1134. doi: 10.1126/science.aao6708. No abstract available.

PMID:
29191895
6.

A Prize for Cancer Prevention.

Varmus H.

Cell. 2017 Oct 5;171(2):495. doi: 10.1016/j.cell.2017.09.038. No abstract available.

7.

A Prize for Cancer Prevention.

Varmus H.

Cell. 2017 Sep 21;171(1):14-17. doi: 10.1016/j.cell.2017.08.020. Epub 2017 Sep 6.

8.

How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?

Varmus H, Unni AM, Lockwood WW.

Cold Spring Harb Symp Quant Biol. 2016;81:247-255. doi: 10.1101/sqb.2016.81.030866. Epub 2017 Jan 25. Review.

PMID:
28123049
9.

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.

McFadden DG, Politi K, Bhutkar A, Chen FK, Song X, Pirun M, Santiago PM, Kim-Kiselak C, Platt JT, Lee E, Hodges E, Rosebrock AP, Bronson RT, Socci ND, Hannon GJ, Jacks T, Varmus H.

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6409-E6417. Epub 2016 Oct 4.

10.

Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival.

Fei DL, Motowski H, Chatrikhi R, Prasad S, Yu J, Gao S, Kielkopf CL, Bradley RK, Varmus H.

PLoS Genet. 2016 Oct 24;12(10):e1006384. doi: 10.1371/journal.pgen.1006384. eCollection 2016 Oct.

11.

Toward a Shared Vision for Cancer Genomic Data.

Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, Staudt LM.

N Engl J Med. 2016 Sep 22;375(12):1109-12. doi: 10.1056/NEJMp1607591. No abstract available.

PMID:
27653561
12.

The transformation of oncology.

Varmus H.

Science. 2016 Apr 8;352(6282):123. doi: 10.1126/science.aaf7301. No abstract available.

13.

Varmus Returns to His Roots in Cancer Genetics.

Varmus H, Kuehn BM.

JAMA. 2015 Jul 7;314(1):13-4. doi: 10.1001/jama.2015.4231. No abstract available.

PMID:
26151250
14.

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.

Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H.

Elife. 2015 Jun 5;4:e06907. doi: 10.7554/eLife.06907.

15.

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.

Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, Zhang X, Webster JD, Ritt D, Ghosal S, Hoschuetzky H, Simpson RM, Biswas R, Politi K, Morrison DK, Varmus HE, Guha U.

Cancer Discov. 2015 May;5(5):534-49. doi: 10.1158/2159-8290.CD-14-0750. Epub 2015 Mar 3.

16.

Opinion: Addressing systemic problems in the biomedical research enterprise.

Alberts B, Kirschner MW, Tilghman S, Varmus H.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):1912-3. doi: 10.1073/pnas.1500969112. No abstract available.

17.

A new initiative on precision medicine.

Collins FS, Varmus H.

N Engl J Med. 2015 Feb 26;372(9):793-5. doi: 10.1056/NEJMp1500523. Epub 2015 Jan 30.

18.

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.

Song X, Fan PD, Bantikassegn A, Guha U, Threadgill DW, Varmus H, Politi K.

Cancer Res. 2015 Mar 15;75(6):1035-45. doi: 10.1158/0008-5472.CAN-13-1625. Epub 2015 Jan 16.

19.

National Cancer Institute-supported clinical trials networks.

Abrams J, Kramer B, Doroshow JH, Varmus H.

J Clin Oncol. 2015 Jan 20;33(3):293. doi: 10.1200/JCO.2014.59.5421. Epub 2014 Dec 1. No abstract available.

PMID:
25452448
20.

Rescuing US biomedical research from its systemic flaws.

Alberts B, Kirschner MW, Tilghman S, Varmus H.

Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5773-7. doi: 10.1073/pnas.1404402111. Epub 2014 Apr 14.

Supplemental Content

Loading ...
Support Center